Stocktoria
Opus Genetics, Inc. IRD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-11-30
Opus Genetics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589,000 |
| Operating income | -$38.6M | -$62.1M | -$10.6M | $18.2M | -$22.7M |
| Interest expense | — | — | $0 | $9,000 | $2,000 |
| Income tax | $0 | $0 | $12,000 | $315,000 | $0 |
| Net income | -$49.6M | -$57.5M | -$10.0M | $17.9M | -$56.7M |
| EPS (diluted) | $-0.80 | $-2.15 | $-0.46 | $0.87 | $-3.82 |
| Operating cash flow | -$35.3M | -$25.6M | -$1.1M | $14.3M | -$19.4M |
| Cash & equivalents | $45.1M | $30.3M | $50.5M | $42.6M | $24.5M |
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M | $26.1M |
| Total liabilities | $34.9M | $11.3M | $4.0M | $2.8M | $3.9M |
| Shareholders' equity | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M |
Source: SEC EDGAR filings · CIK 0001228627 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.